Discovery of 1-Amino-5H-pyrido[4,3-b]indol-4-carboxamide Inhibitors of Janus Kinase 2 (JAK2) for the Treatment of Myeloproliferative Disorders

被引:61
作者
Lim, Jongwon [1 ]
Taoka, Brandon [1 ]
Otte, Ryan D. [1 ]
Spencer, Kerrie [1 ]
Dinsmore, Christopher J. [1 ]
Altman, Michael D. [4 ]
Chan, Grace [3 ]
Rosenstein, Craig [3 ]
Sharma, Sujata [6 ]
Su, Hua-Poo [6 ]
Szewczak, Alexander A. [3 ]
Xu, Lin [5 ]
Yin, Hong [5 ]
Zugay-Murphy, Joan [6 ]
Marshall, C. Gary [2 ]
Young, Jonathan R. [1 ]
机构
[1] Merck & Co Inc, Dept Chem, Boston, MA 02115 USA
[2] Merck & Co Inc, Dept Oncol, Boston, MA 02115 USA
[3] Merck & Co Inc, Dept Vitro Pharmacol, Boston, MA 02115 USA
[4] Merck & Co Inc, Dept Chem Modeling & Informat, Boston, MA 02115 USA
[5] Merck & Co Inc, Dept Drug Metab & Pharmacokinet, Boston, MA 02115 USA
[6] Merck & Co Inc, Dept Struct Chem, Boston, MA 02115 USA
关键词
POLYCYTHEMIA-VERA; MUTATION; EXPRESSION; BINDING; SERIES; STATS;
D O I
10.1021/jm200909u
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The JAK-STAT pathway mediates signaling by cytokines, which control survival, proliferation, and differentiation of a variety of cells. In recent years, a single point mutation (V617F) in the tyrosine kinase JAK2 was found to be present with a high incidence in myeloproliferative disorders (MPDs). This mutation led to hyperactivation of JAK.2, cytokine-independent signaling, and subsequent activation of downstream signaling networks. The genetic, biological, and physiological evidence suggests that JAK2 inhibitors could be effective in treating MPDs. De novo design efforts of new scaffolds identified 1-amino-5H-pyrido [4,3-b]indol-4-carboxamides as a new viable lead series. Subsequent optimization of cell potency, metabolic stability, and off-target activities of the leads led to the discovery of 7-(2-aminopyrimidin-5-yl)-1-{[(1R)-1-cyclopropyl-2,2,2-trifluoroethyl]amino}-5H-pyrido[4,3-b]indole-4-carboxamide (65). Compound 65 is a potent, orally active inhibitor of JAK2 with excellent selectivity, PK profile, and in vivo efficacy in animal models.
引用
收藏
页码:7334 / 7349
页数:16
相关论文
共 40 条
[11]  
Kraus M., UNPUB
[12]   JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis [J].
Lacout, Catherine ;
Pisani, Didier F. ;
Tulliez, Micheline ;
Gachelin, Francoise Moreau ;
Vainchenker, William ;
Villeval, Jean-Luc .
BLOOD, 2006, 108 (05) :1652-1660
[13]   Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis [J].
Levine, RL ;
Wadleigh, M ;
Cools, J ;
Ebert, BL ;
Wernig, G ;
Huntly, BJP ;
Boggon, TJ ;
Wlodarska, L ;
Clark, JJ ;
Moore, S ;
Adelsperger, J ;
Koo, S ;
Lee, JC ;
Gabriel, S ;
Mercher, T ;
D'Andrea, A ;
Fröhling, S ;
Döhner, K ;
Marynen, P ;
Vandenberghe, P ;
Mesa, RA ;
Tefferi, A ;
Griffin, JD ;
Eck, MJ ;
Sellers, WR ;
Meyerson, M ;
Golub, TR ;
Lee, SJ ;
Gilliland, DG .
CANCER CELL, 2005, 7 (04) :387-397
[14]  
Littke AF, 1998, ANGEW CHEM INT EDIT, V37, P3387, DOI 10.1002/(SICI)1521-3773(19981231)37:24<3387::AID-ANIE3387>3.0.CO
[15]  
2-P
[16]   Synthesis of enantiomerically pure N-tert-butanesulfinyl imines (tert-butanesulfinimines) by the direct condensation of tert-butanesulfinamide with aldehydes and ketones [J].
Liu, GC ;
Cogan, DA ;
Owens, TD ;
Tang, TP ;
Ellman, JA .
JOURNAL OF ORGANIC CHEMISTRY, 1999, 64 (04) :1278-1284
[17]   Janus kinase 2 inhibitors in myeloproliferative disorders [J].
Lucia, Eugenio ;
Recchia, Anna Grazia ;
Gentile, Massimo ;
Bossio, Sabrina ;
Vigna, Ernesto ;
Mazzone, Carla ;
Madeo, Antonio ;
Morabito, Lucio ;
Gigliotti, Vincenzo ;
De Stefano, Laura ;
Caruso, Nadia ;
Servillo, Pasquale ;
Franzese, Stefania ;
Bisconte, Maria Grazia ;
Gentile, Carlo ;
Morabito, Fortunato .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (01) :41-59
[18]   SYNTHESIS OF A SERIES OF COMPOUNDS RELATED TO BETAXOLOL, A NEW BETA-1-ADRENOCEPTOR ANTAGONIST WITH A PHARMACOLOGICAL AND PHARMACOKINETIC PROFILE OPTIMIZED FOR THE TREATMENT OF CHRONIC CARDIOVASCULAR-DISEASES [J].
MANOURY, PM ;
BINET, JL ;
ROUSSEAU, J ;
LEFEVREBORG, FM ;
CAVERO, IG .
JOURNAL OF MEDICINAL CHEMISTRY, 1987, 30 (06) :1003-1011
[19]   An inhibitor of Janus kinase 2 prevents polycythemia in mice [J].
Mathur, Anjili ;
Mo, Jan-Rung ;
Kraus, Manfred ;
O'Hare, Erin ;
Sinclair, Peter ;
Young, Jonathan ;
Zhao, Shuxia ;
Wang, Yuxun ;
Kopinja, Johnny ;
Qu, Xianlu ;
Reilly, John ;
Walker, Deborah ;
Xu, Lin ;
Aleksandrowicz, Daniel ;
Marshall, Gary ;
Scott, Martin L. ;
Kohl, Nancy E. ;
Bachman, Eric .
BIOCHEMICAL PHARMACOLOGY, 2009, 78 (04) :382-389
[20]   Phaser crystallographic software [J].
McCoy, Airlie J. ;
Grosse-Kunstleve, Ralf W. ;
Adams, Paul D. ;
Winn, Martyn D. ;
Storoni, Laurent C. ;
Read, Randy J. .
JOURNAL OF APPLIED CRYSTALLOGRAPHY, 2007, 40 :658-674